Letrozole 2.5 MG tablet 90S
Ended Awarded Last action
- Contract number
- SPE2DR26FFAC8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,047
Award facts
- Contract value 100% obligated
- $1,047.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $1,047.30 to DMS Pharmaceutical Group Inc. for 90 tablets of Letrozole 2.5 mg on December 11, 2025, with completion targeted for December 12, 2025. This firm fixed-price delivery order represents a routine pharmaceutical supply transaction issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency. The award carries no set-aside designation, indicating it was competed on an unrestricted basis. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected as the awardee based on its established capacity to supply pharmaceutical products to Department of Defense medical facilities.
This delivery order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion Defense Logistics Agency acquisition strategy designed to streamline pharmaceutical sourcing for military healthcare operations. DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract under this program with a $499.99 million ceiling and completion date of December 31, 2036, structured with a 30-month base period and three 30-month option periods. The company's substantial federal contracting activity demonstrates its critical role in the military medical supply chain, supplying an extensive portfolio ranging from routine medications to specialized oncology treatments, biologics, and medical devices to support Department of Defense healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FFAC8?
SPE2DR26FFAC8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 11, 2025.
How much is contract SPE2DR26FFAC8 worth?
The government has obligated $1,047 on SPE2DR26FFAC8.
Is contract SPE2DR26FFAC8 an order under another contract?
Yes. SPE2DR26FFAC8 is a delivery order under SPE2DR25D9223, an indefinite delivery contract.
Was contract SPE2DR26FFAC8 competed?
The extent of competition for SPE2DR26FFAC8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award